BCL2 and B-cell chronic lymphocytic leukemia: Despite the improved management of CLL achieved over the past years [5], the persistence of CLL cells after therapy (i.e., minimal residual diseases, MRD) ultimately leads to disease relapse [6], which holds true also in the current era of new CLL-targeted therapies, including Bruton’s Tyrosine Kinase inhibitors (BTKi) (ibrutinib and acalabrutinib), B-cell lymphoma 2 (BCL2) inhibitors (venetoclax) and phosphoinositide 3-kinase inhibitors (idelalisib) [7,8,9,10,11,12,13,14,15].